Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fi - Wikidata - awgldk - TriplyDB

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fi

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fi

http://www.wikidata.org/entity/Q37412869

about

Single or dual antiplatelet therapy after PCI.Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis.Anticoagulation after coronary stenting: a systemic review.Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.Antithrombotic therapy in 2017: Advances in atherosclerosis, atrial fibrillation, and valvular disease.Safety and Efficacy of Triple Therapeutic Targets with Rivaroxaban after Acute Myocardial Infarction Complicated by Left Ventricular Thrombi in a Case of Nonvalvular Atrial Fibrillation.Optimum Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation and Undergoing Percutaneous Coronary Intervention.Comparative Review of Oral P2Y12 Inhibitors.Effects of atrial fibrillation on complications and prognosis of patients receiving emergency PCI after acute myocardial infarction

P2860

Q38970275-3A85C88A-4FE4-4E2A-9805-3DFF14C0CD95 Q39295736-15E555DF-D510-40D9-B03F-F61F947DC341 Q45795390-86F6FC94-2322-4526-AC61-536D3E5F5011 Q47984703-E1A4E5AB-9F31-47C3-9062-9D19EB8412F1 Q48508504-B1982DB0-1CFC-4F0C-A0E3-4786F2DF3C1A Q49347684-0F168D72-1037-4624-A0B9-E8EF30948566 Q52310273-F7C3872C-4AF6-488A-B767-31900C2DE8B2 Q55105393-06728B68-719E-4F45-9E6E-3B1997896BC1 Q55396201-7779B11C-C337-4702-AACA-DDA09E42151F Q58718076-B27C36A8-0BD5-4CC3-8D4D-07C040F23DFC

P2860

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fi

http://www.wikidata.org/entity/Q37412869

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Design and Rationale of the RE ...... nts With Nonvalvular Atrial Fi

@en

Design and Rationale of the RE ...... nts With Nonvalvular Atrial Fi

@nl

type

label

Design and Rationale of the RE ...... nts With Nonvalvular Atrial Fi

@en

Design and Rationale of the RE ...... nts With Nonvalvular Atrial Fi

@nl

prefLabel

Design and Rationale of the RE ...... nts With Nonvalvular Atrial Fi

@en

Design and Rationale of the RE ...... nts With Nonvalvular Atrial Fi

@nl

P1433

Q37412869-FABFB2C4-6C03-4F7C-AF79-A5843181E8A1

P1476

Q37412869-29B1BCA9-7BA8-4CEE-8E4D-1CEA59B120DD

P2093

Q37412869-29522C62-996A-4C19-9B87-F7CA75B11DE2

Q37412869-3B428D78-44BB-4879-8ED7-E0883A121FF2

Q37412869-4612EAB6-F2E0-4AA0-9B66-83550594A723

Q37412869-574B9F9C-9F0A-4982-BE01-1834E94B2A07

Q37412869-7885352F-B094-40E5-BEB6-AB2CAF093BC8

Q37412869-7E17ADBA-1D15-4FA1-A3A1-89704C681ACF

Q37412869-8FA8CBC8-DEBF-4F5B-8FDE-C2285636D09A

Q37412869-91150638-08B1-4C1B-A252-56A85A04FEAA

Q37412869-956FDB03-100E-48F5-82D0-E36F48EDBF9C

Q37412869-CCD31B5F-4DAA-4E53-BB2D-D5810710DE0A

P2860

Q37412869-09F85E49-66E7-4F11-8AA2-03A5E4F08C87

Q37412869-0DB88F9A-73FC-4AEB-98FB-849711A61E2A

Q37412869-137F2B8B-E40F-4F09-B362-C40F42FF8031

Q37412869-14C0B5DB-B8D3-46B0-BFE0-DCD0827BA18B

Q37412869-167DBCD0-4AFA-4026-A262-9EE3B8DEE0A5

Q37412869-1D0804CE-9063-48FE-AF28-89F5FD000FDA

Q37412869-2A58E43A-B0A0-482E-B563-2CAF205C54FB

Q37412869-2C1562BD-2D14-4B9F-B9CB-57CE5685AF13

Q37412869-32ED3A7A-1461-456B-A867-9D784918AE37

Q37412869-3C70E544-167F-4FB6-9C9A-61E2057C5362

P304

Q37412869-51FA3520-6AD7-4820-B466-FECB419A643D

P31

Q37412869-E2B86477-EEFD-41A4-9B4D-1073AEC41675

P356

Q37412869-2EDC599C-127D-494E-93B8-EB2A024E6443

P433

Q37412869-3CE6D6CE-E4B1-4C33-8EB2-F6BB5735EC97

P478

Q37412869-9E60B1F0-5252-49B4-84F5-687F592F771B

P50

Q37412869-2DB28C2E-56AC-4B8A-89A5-1B7025D39615

Q37412869-71B452E0-FBE4-410A-A61C-2CAEB5E1F6D4

Q37412869-85B3EAD8-2FDF-4842-95D5-7B6D2912D167

P577

Q37412869-43D6DEB9-E63E-47C1-8E36-F81562F88F22

P698

Q37412869-CEEDD984-0908-4AB8-8A5C-E3066F2E76DD

P932

Q37412869-0D540FC1-7C41-47EA-82CC-782E4CC27F9D

P356

P1433

Clinical Cardiology

P1476

Design and Rationale of the RE ...... nts With Nonvalvular Atrial Fi

@en

P2093

Christopher P Cannon

http://www.w3.org/2001/XMLSchema#string

Ernesto Ferreiros Ripoll

http://www.w3.org/2001/XMLSchema#string

Jenny Manassie

http://www.w3.org/2001/XMLSchema#string

Jon Blatchford

http://www.w3.org/2001/XMLSchema#string

Jonas Oldgren

http://www.w3.org/2001/XMLSchema#string

Joseph M Massaro

http://www.w3.org/2001/XMLSchema#string

Jurriën M Ten Berg

http://www.w3.org/2001/XMLSchema#string

Jörg Kreuzer

http://www.w3.org/2001/XMLSchema#string

Martina Brueckmann

http://www.w3.org/2001/XMLSchema#string

Ph Gabriel Steg

http://www.w3.org/2001/XMLSchema#string

P2860

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Dabigatran versus warfarin in patients with atrial fibrillation

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.

P304

555-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CLC.22572

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Deepak L. Bhatt

Gregory Y. H. Lip

Stephen G. Ellis

P577

2016-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27565018

http://www.w3.org/2001/XMLSchema#string

P932

5108471

http://www.w3.org/2001/XMLSchema#string